The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. About Tiziana Life Sciences.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. Notes: The following tables contain the key data for the Bayer Group and its divisions for the first quarter of 2021.

Sales 40

Sales Production Marketing Containment 40

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. It contains the antiviral medications nirmatrelvir and ritonavir. billion in 2022. and $16,382.51

Sales 98

Sales Manufacturing FDA Approval Life Science 98